DOCSLIB.ORG

Piportil Depot 50 Mg/Ml

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Piportil Depot 50 Mg/Ml Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Piportil Depot 50 mg/ml. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pipotiazine palmitate 50 mg/ml. For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Depot injection. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the maintenance treatment of schizophrenia and paranoid psychoses and prevention of relapse, especially where compliance with oral medication is a problem 4.2 Posology and method of administration Patients should be stabilised on Piportil Depot under psychiatric supervision. Administration should be by deep intramuscular injection into the gluteal region. Wide variation of response can be expected. The following dosage recommendations are suitable for either indication. Adults: Initially 25mg should be given to assess the response of the patient to the drug. Further doses should be administered at appropriate intervals, increasing by increments of 25 or 50 mg until a satisfactory response is obtained. In clinical practice, Piportil Depot has been shown to have a long duration of action, allowing intervals of 4 weeks between injections for maintenance therapy. Dosage should be adjusted under close supervision to suit each individual patient in order to obtain the best therapeutic response compatible with tolerance. The duration of action depends on the dose administered, allowing dosage intervals to be varied to suit individual circumstances. Most patients respond favourably to a dose of 50-100 mg every 4 weeks, the maximum recommended dose is 200 mg every four weeks. Elderly : Neuroleptics should be used cautiously in the elderly: A reduced starting dose is recommended, ie 5-10 mg might be considered. Children: Not recommended for use in children. 4.3 Contraindications Piportil Depot should not be administered to patients in a comatose state or with marked cerebral atherosclerosis, phaeochromocytoma, renal or liver failure, severe cardiac insufficiency or hypersensitivity to other phenothiazine derivatives. 4.4 Special warnings and precautions for use Piportil Depot should be used with caution in patients suffering from or who have a history of, the following conditions: severe respiratory disease, epilepsy, alcohol withdrawal symptoms, brain damage, Parkinson's disease or marked extrapyramidal symptoms with previously used neuroleptics, personal or family history of narrow angle glaucoma, hypothyroidism, myasthenia gravis, prostatic hypertrophy, thyrotoxicosis. Care is required in very hot or very cold weather particularly in elderly frail patients. Neuroleptic phenothiazines may potentiate QT interval prolongation which increases the risk of onset of serious ventricular arrhythmias of the torsade de pointes type, which is potentially fatal (sudden death). QT prolongation is exacerbated, in particular, in the presence of bradycardia, hypokalaemia, and congenital or acquired (i.e. drug induced) QT prolongation. The risk-benefit should be fully assessed before Piportil treatment is commenced. If the clinical situation permits, medical and laboratory evaluations (e.g. biochemical status and ECG) should be performed to rule out possible risk factors (e.g. cardiac disease; family history of QT prolongation; metabolic abnormalities such as hypokalaemia, hypocalcaemia or hypomagnesaemia; starvation; alcohol abuse; concomitant therapy with other drugs known to prolong the QT interval) before initiating treatment with Piportil and during the initial phase of treatment, or as deemed necessary during the treatment (see also sections 4.5 and 4.8). Avoid concomitant treatment with other neuroleptics (see section 4.5). Stroke: In randomised clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism of such risk increase is not known. An increase in the risk with other antipsychotic drugs or other populations of patients cannot be excluded. Piportil should be used with caution in patients with stroke risk factors. Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have been described after abrupt cessation of antipsychotic drugs. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported. Therefore, gradual withdrawal is advisable. Hyperglycaemia or intolerance to glucose has been reported in patients treated with antipsychotic phenothiazines. Patients with an established diagnosis of diabetes mellitus or with risk factors for the development of diabetes who are started on Piportil, should get appropriate glycaemic monitoring during treatment (see section 4.8). Increased Mortality in Elderly people with Dementia Data from two large observational studies showed that elderly people with dementia who are treated with antipsychotics are at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. Piportil Depot is not licensed for the treatment of dementia-related behavioural disturbances. Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with Piportil Depot and preventive measures taken. 4.5 Interaction With Other Medicaments and Other Forms of Interaction There is an increased risk of arrhythmias when antipsychotics are used with concomitant QT prolonging drugs (including certain antiarrhythmics, antidepressants and other antipsychotics) and drugs causing electrolyte imbalance The CNS depressant actions of neuroleptic agents may be intensified (additively) by alcohol, barbiturates and other sedatives. Respiratory depression may occur. The hypotensive effect of most antihypertensive drugs especially alpha adrenoceptor blocking agents may be exaggerated by neuroleptics. This effect may also be observed with anaesthetics and opioid analgesics. The mild anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc. The action of some drugs may be opposed by phenothiazine neuroleptics; these include amfetamine, levodopa, apomorphine, lisuride, pergolide, bromocriptine, cabergoline, clonidine, guanethidine, adrenaline. Some drugs may possibly enhance the effects of phenothiazines including cimetidine. Anticholinergic agents may reduce the antipsychotic effect of neuroleptics. Some drugs interfere with absorption of neuroleptic agents: antacids, kaolin, anti-Parkinson drugs, lithium. Increases or decreases in the plasma concentrations of a number of drugs, e.g. propranolol, phenobarbital have been observed but were not of clinical significance. Concomitant use with ritonavir may possibly increase the plasma concentration of the antipsychotic. High doses of neuroleptics reduce the response to hypoglycaemic agents, the dosage of which might have to be raised. There is an increased risk of extrapyramidal effects with tetrabenazine and lithium, and an increased possibility of neurotoxicity with lithium. Sibutramine can lead to an increased risk of CNS toxicity. Adrenaline must not be used in patients overdosed with phenothiazine neuroleptics. Most of the above interactions are of a theoretical nature and not dangerous. Simultaneous administration of desferrioxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy characterised by loss of consciousness for 48--72 hours. It is possible that this may occur with Piportil since it shares many of the pharmacological properties of prochlorperazine. Avoid concomitant use of Clozapine with depot formulation as it cannot be withdrawn quickly if neutropenia occurs. 4.6 Pregnancy and Lactation There is inadequate evidence of safety of Piportil Depot in human pregnancy, although animal studies have shown no hazard. The drug should not be used during pregnancy or lactation unless the physician considers it essential. 4.7 Effects on Ability to Drive and Use Machines Patients should be warned about drowsiness especially at the start of treatment and advised not to drive or operate machinery. 4.8 Undesirable Effects Minor side effects of neuroleptics are drowsiness, especially at the start of treatment, nasal stuffiness, dry mouth, insomnia, agitation and weight gain. Other possible adverse effects are as follows:- Liver function: jaundice, usually transient, occurs in a very small percentage of patients taking neuroleptics. A premonitory sign may be a sudden onset of fever after one to three weeks of treatment followed by the development of jaundice. Neuroleptic jaundice has the biochemical and other characteristics of obstructive jaundice and is associated with obstructions of the canaliculi by bile thrombi: the frequent presence of an accompanying eosinophilia indicates the allergic nature of this phenomenon. Treatment should be withheld on the development of jaundice. Cardiorespiratory: hypotension, usually postural, commonly occurs. Elderly or volume depleted subjects are particularly susceptible: it is more likely to occur after intramuscular administration. Cardiac arrhythmias, including atrial arrhythmia, A - V block, ventricular
Load more

Recommended publications
  • Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
    DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics
    CHAPTER 15 _ Studies with Lysergic Acid Diethylamide in Regressed Schizophrenics By FREDERICK B. CHARAT AN, M.D. OF THE MANY studies carried out with lysergic acid diethylamide in the last 15 years, relatively few have dealt with regressed schizophrenics. Most workers have used comparatively small doses of LSD. Some gave up to 600 gamma orally. Others reported the effects of up to 500 gamma intra- muscularly, 180 gamma intravenously and 60 gamma intrathecally in small series of cases. Several investigators agreed that in chronic schizophrenics higher doses of LSD than those administered to undeteriorated schizo- phrenics and nonpsychotics have been required to produce psychic effects. Apart from the slight response of chronic schizophrenics to doses of LSD which lead to marked and characteristic effects in other subjects, tolerance to the drug seems to develop in as brief a period as three days. These differences in response to LSD pose some interesting problems. Is the lack of response in chronic schizophrenics merely an apparent one caused by their inability to communicate their inner experiences? Is it due to the development of some immune state connected with biochemical alter- ations produced during the psychosis? Is it the reflection of a metabolic difference between schizophrenics and non-schizophrenics? May it be a general manifestation of schizophrenic underresponsiveness to virtually any stress, once the chronic stagnant phase of the psychosis has been reached? Clear answers to all these questions cannot yet be given. The present investi- gation was undertaken to examine further the responses of chronic schizo- phrenics to large doses of LSD and also to observe the effect of other drugs upon this response.
    [Show full text]
  • Perphenazine-151548-PI.Pdf
    PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg , 4 mg, 8mg, and 16 mg Antipsychotic/Antiemetic AA Pharma Inc. DATE OF REVISION: April 12, 2012 1165 Creditsone Road, Unit #1 Vaughan, Ontario L4K 4N7 Control Number: 151548 PRESCRIBING INFORMATION PERPHENAZINE Perphenazine Tablets USP 2 mg, 4 mg, 8 mg and 16 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Perphenazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Perphenazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Perphenazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes. Duration of action is 3 to 4 hours. Perphenazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Perphenazine enters the enterohepatic circulation and is excreted chiefly in the feces. INDICATIONS AND CLINICAL USE Perphenazine is indicated in the management of manifestations of psychotic disorders. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. 1 Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated in severely depressed patients, in the presence of blood dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or in patients with severe cardiovascular disorders or a history of hypersensitivity to phenothiazine derivatives.
    [Show full text]
  • Preparation of Metabolites by Chemical Reaction: Conversion of Antipsychotic Phenothiazines to Their Sulfoxides and Tertiary
    396 Journal of Health Science, 50(4) 396–406 (2004) Preparation of Metabolites N-oxides from parent drug could be confirmed when the collisional energy was decreased to 10 eV. 1H- and by Chemical Reaction: 13C-NMR spectral data confirmed the structure of the Conversion of Antipsychotic prepared mianserin N-oxide to be 2-oxide. In conclu- sion, a simple and rapid preparation method for oxide Phenothiazines to their metabolites of phenothiazines and tertiary amino cy- Sulfoxides and Tertiary clic antidepressants available as analytical standards was established. Amino Cyclic Key words —–— metabolite, chemical preparation, ox- Antidepressants ide, phenothiazine, cyclic antidepressants, mass spectros- to their N-Oxide with copy Hydrogen Peroxide Using Titanosilicate INTRODUCTION Catalyst The identification and quantification of drugs Akira Ogamo* and Mariko Fukumoto ingested into human bodies require comprehensive information covering the target drugs themselves and School of Pharmaceutical Sciences, Kitasato University, their metabolites. To carry out a quantitative analy- Shirokane 5–9–1, Minato-ku, Tokyo 108–8641, Japan sis, the standard substances of metabolites are es- (Received March 5, 2004; Accepted April 11, 2004) sential. Some important metabolites can be obtained as commercial products, but many metabolites, es- The aim of this study was to establish a prepara- pecially those of new drugs, are difficult to obtain tion method needed to analyze the metabolites of an as standard samples. These problems have been analytical procedure for antipsychotic phenothiazines solved by using experimental animals or isolated and tertiary amino cyclic antidepressants by chemical enzyme systems originating from biological mate- reaction. These drugs were oxidized to their sulfoxide rials.
    [Show full text]
  • Phenothiazine Poisoning a Review of 48 Cases
    Refer to: Barry D, Meyskens FL Jr, Becker CE: Phenothiazine poison- ing-A review of 48 cases. Calif Med 118:1-5, Jan 1973 California Medicine THE WESTERN JOURNAL OF MEDICINE Phenothiazine Poisoning A Review of 48 Cases DANIEL BARRY, B.A., FRANK L. MEYSKENS, JR., M.D., AND CHARLES E. BECKER, M.D., San Francisco * Of 48 cases of phenothiazine poisoning that were analyzed, 34 were attributed to stuicide attempts, nine to accidental ingestion, and five to drug reactions. As outpatient treatment of schizophrenia increases, cases of over- dose with phenothiazine drugs may be expected to increase also. The prescribing of multiple phenothiazines and antidepressants is probably contributory to the occurrence of mixed drug ingestions. The symptoms and signs of phenothiazine poisoning are largely predictable if the atropine-like, alpha-blocking, quinidine-like, and extrapyramidal actions of phenothiazines are appreciated, Unexplain- able tachypnea and paradoxical miosis were noted in severe cases. In one case in the study phenothiazine intoxication was present in the newborn infant of a schizophrenic mother. PHENOTHIAZINES ARE BECOMING household drugs tionable advertising campaigns advocating phe- in Califomnia. The closing of state hospitals with nothiazines for the treatment of a wide variety the concomitant institution of mass outpatient of ailments have made these drugs generally treatment of chronic schizophrenics through com- available. The high incidence of schizophrenia munity mental health centers, and recent quesv in young adulthood and the increasing suicide From the Detoxification Unit, San Francisco General Hospital, and rate in this age group" suggest that phenothia- the Department of Clinical Pharmacology, University of California, San Francisco.
    [Show full text]
  • Neuroleptic Malignant Syndrome in a Patient
    Psychiatria Danubina, 2018; Vol. 30, Suppl. 7, pp 415-417 Conference paper © Medicinska naklada - Zagreb, Croatia NEUROLEPTIC MALIGNANT SYNDROME IN A PATIENT TREATED WITH CLOTIAPINE Clémentine Lantin, Miriam Franco, François-Xavier Dekeuleneer, Didier Chamart & Juan Martin Tecco Mental Health Unit, Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage (CHUP-MB), Mons, Belgium SUMMARY Background: Neuroleptic malignant syndrome (NMS), which is linked to the use of antipsychotic medication, is a potentially lethal neurological emergency. The interest of our study is that NMS induced by the use of clotiapine has never previously been described. Subjects and methods: We present the case of a 61-year old man whose sleep disorders were treated with clotiapine 40 mg/day. After 7 days of taking 40 mg clotiapine, the patient presented with a deterioration of his general health which had gradually taken hold, with altered consciousness accompanied by generalised muscle rigidity and hypersalivation. Laboratory blood tests revealed elevated levels of Creatine Phosphokinase (CPK) at 812 U/l. The patient was diagnosed with NMS and treated accordingly. Results: The mechanism that underlies the appearance of NMS remains largely unknown. Clotiapine is a second-generation antipsychotic, first released onto the market in the 1970s, and is available in a few countries, including Belgium. NMS is treated as a medical emergency due to the possibility of morbidity and death. The first step in the treatment of NMS consists in withholding the agent suspected of provoking the symptoms. Conclusions: NMS is difficult to diagnose due to a great variability in clinical presentations and the absence of specific tests and laboratory results.
    [Show full text]
  • Trilafon Tablets & Trilafon Injection Final Printed Labeling
    PAGE 1 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 1 TRILAFON Ò 2 brand of perphenazine, USP 3 Tablets, 4 Injection 5 6 DESCRIPTION TRILAFON products contain perphenazine, USP (4-[3-(2- 7 chlorophenothiazin-10-yl)propyl]-1-piper-azineethanol), a piperazinyl phenothiazine 8 having the chemical formula, C21H26CIN3OS. They are available as Tablets, 2, 4, 9 8, and 16 mg; and Injection, perphenazine 5 mg per 1 mL. 10 The inactive ingredients for TRILAFON Tablets, 2, 4, 8, and 16 mg, include: 11 acacia, black iron oxide, butylparaben, calcium phosphate, calcium sulfate, 12 carnauba wax, corn starch, lactose, magnesium stearate, sugar, titanium dioxide, 13 and white wax. The inactive ingredients for TRILAFON Injection include: citric 14 acid, sodium bisulfite, sodium hydroxide, and water. 15 ACTIONS Perphenazine has actions at all levels of the central nervous system, 16 particularly the hypothalamus. However, the site and mechanism of action of 17 therapeutic effect are not known. 18 CLINICAL PHARMACOLOGY Pharmacokinetics: Following oral administration 19 of TRILAFON® Tablets, mean peak plasma perphenazine concentrations were 20 observed between 1 to 3 hours. The plasma elimination half-life of perphenazine 21 was independent of dose and ranged between 9 and 12 hours. In a study in which 22 normal volunteers (n=12) received TRILAFON 4 mg q8h for 5 days, steady-state 23 concentrations of perphenazine were reached within 72 hours. Mean (%CV) Cmax 24 and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are 25 listed below: 26 ParameterPerphenazine 7-Hydroxyperphenazine 27 Cmax (pg/mL) 984 (43) 509 (25) 28 Cmin (pg/mL) 442 (76) 350 (56) 1 PAGE 2 TRILAFON TABLETS & TRILAFON INJECTION FINAL PRINTED LABELING 29 Peak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours 30 with a terminal phase half-life ranging between 9.9 to 18.8 hours.
    [Show full text]
  • Psychotropic Medication Audit Criteria and Guidelines
    Psychotropic Medication Audit Criteria and Guidelines Fluphenazine decanoate (Prolixin®, decanoate) and Haloperidol decanoate (Haldol®, decanoate) PEFC Approved: July 2021 Indications Label: ● Patients with schizophrenia who require prolonged parenteral antipsychotic therapy Off label: • Schizoaffective disorder Black Box Warning ● Increased mortality in elderly patients with dementia-related psychosis Contraindications ● Severe central nervous system depression or comatose states from any cause ● Hypersensitivity to the drug or derivatives ● Haloperidol decanoate Parkinson’s disease Dementia with Lewy bodies ● Fluphenazine decanoate Suspected or established subcortical brain damage Receiving large doses of hypnotics Blood dyscrasias Hepatic disease Warnings and Precautions ● Severe cardiovascular disorders ● Concomitant use with other CNS depressants ● Diagnosis of a seizure disorder or history of seizures ● Haloperidol only 1 Texas Health and Human Services ● hhs.texas.gov Antipsychotics-decanoates Must not be administered intravenously. QTc prolonging conditions (electrolyte imbalances, drugs known to prolong QTc, underlying cardiac abnormalities, hypothyroidism, familial long QT-syndrome) Leukopenia/neutropenia Thyrotoxicosis Myasthenia gravis Bipolar disorder ● Fluphenazine only History of cholestatic jaundice, dermatoses, or other allergic reactions to phenothiazine derivatives Reduced amounts of anesthetics or CNS depressants may be necessary Effects of atropine may be potentiated Use caution in patients exposed
    [Show full text]
  • DOMASYS Standard
    New Zealand Data Sheet 04 December 2018 Neulactil-periciazine DATA SHEET 1 NEULACTIL TABLETS Neulactil 2.5 mg tablets Neulactil 10 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Periciazine 2.5mg Periciazine 10mg Excipients with known effect: lactose monohydrate and wheat starch For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Neulactil tablets 2.5 mg: yellow, scored, marked NEULACTIL 10 mg: yellow, scored, marked 10 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Periciazine is indicated: 1. In adults with schizophrenia or other psychoses, for the treatment of symptoms or prevention of relapse. 2. In anxiety, psychomotor agitation, violent or dangerously impulsive behaviour. periciazine is used as an adjunct to the short-term management of these conditions. Periciazine tablets are not recommended for children (see Section 4.3 and 4.4). neulactil-ccsiv4-dsv11-04dec18 Page 1 New Zealand Data Sheet 04 December 2018 Neulactil-periciazine 4.2 DOSE AND METHOD OF ADMINISTRATION Dosage requirements vary with the individual and the severity of the condition being treated. Initial dosage should be low with progressive increases until the desired response is obtained, after which dosage should be adjusted to maintain control of symptoms. Severe conditions (Indication 1) Adults Initially 75 mg per day in divided doses. Dosage should be increased by 25 mg per day at weekly intervals until optimum effect is achieved. Maintenance therapy would not normally be expected to exceed 300mg per day. Elderly Initially 15-30 mg per day in divided doses. If this is well tolerated the dosage may be increased if necessary for optimum control of behaviour.
    [Show full text]
  • Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper
    No. 6] Proc. Japan Acad., 46 (1970) 583 136. Studies on Screening Test for Lysergic Acid Diethylamide by Test Paper By Tetsukichi NIwAGudHTand Takako INOUE National Research Institute of Police Science, Tokyo (Comm.by TanemotoFURUHATA. M.J. A.,June 12, 1970) Various analytical methods for lysergic acid diethylamide (LSD) have been reported and some of them are based on a specific colora- tion of LSD by p-dimethylaminobenzaldehyde. Look has suggested a method for field screening test of LSD using this reagent.i~ It is purpose of this paper to establish a method for screening of LSD by test paper. Experimental. Material. The samples used in this experiment are as follows. LSD, seven kinds of antifebrics and analgesics, eighteen kinds of hypnotics, sixteen kinds of tranquilizers, two kinds of antihistaminics, seven kinds of local anaesthetics, twenty-nine kinds of other drugs, twenty-six kinds of alkaloids and narcotics, and eight kinds of amino acids. Forms of LSD and drugs used are as follows. LSD: pure powder, tablet containing 50 p g of LSD (90% of lactose, 7 % of starch and 3% of talc are mixed, ethanol solution containing 50 pg of LSD is added, the solvent is evaporated and tablet with 8 mm in diameter and 2 mm in thickness is prepared), and sugar cube con- taining 40 pg of LSD (6.3 g of sugar cube is soaked in ethanol solu- tion containing 40 pg of LSD and air-dried). Drugs : pure powder. Reagent. 1. Preparation of test paper. Filter paper (Toyo Roshi No. 131) is soaked in a solution of 2 % p-dimethylamino- benzaldehyde in ethanol, dried in air and cut into strips for test paper.
    [Show full text]
  • Antipsychotics-Children-Surveillance
    AHRQ Comparative Effectiveness Review Surveillance Program CER #39: First & second generation antipsychotics for children and young adults Original Release Date: February, 2012 Surveillance Report: November, 2012 Surveillance Report: October, 2014 Summary of Key Findings from Surveillance Reports: • For Key Question 1, studies were identified suggesting that conclusions related to the effectiveness of Second Generation Antidepressants (SGA) for anorexia nervosa are out of date, that conclusions related to the comparative effectiveness of First Generation Antidepressants (FGA) and SGAs are possibly out of date, that the conclusion of no difference between SGAs and placebo for aggression is possibly out of date, that the strength of evidence (SOE) for SGAs and improvement on mania scales may possibly increase from low to moderate, and the SOE regarding risperidone and reduction in problem behavior may have increased. • For Key Question 2, conclusions related to cardiovascular events and weight gain, and the tolerability of molidone hydrochloride are possibly out of date, and the SOE for additional adverse events may possibly increase from moderate to high. • For Key Question 3, the conclusion on the safety and tolerability of FGAs vs. SGAs is possibly out of date. • For Key Question 4, conclusions related to individuals with comorbid disorders are possibly out of date. Signal Assessment: The signals examined in this surveillance assessment suggest that the original CER is possibly out of date. i Authors: Karli Kondo Maya O’Neil Shammarie Mathis Ryan McKenna Kelly Vander Ley Johanna Anderson Mark Helfand Conflict of Interest: None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
    [Show full text]